Lv1
40 积分 2025-01-07 加入
Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial
19小时前
待确认
[Accelerating the construction of digital and intelligentialized pathology and the prospects]
1个月前
已完结
The global burden of lymphoma: estimates from the Global Burden of Disease 2019 study
1个月前
已完结
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
1个月前
已完结
Real-World Evaluation of Treatment Patterns and Clinical Outcomes among Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Asciminib in Clinical Practice in the United States
3个月前
已完结
Asciminib as a third line option in chronic myeloid leukemia
3个月前
已完结
Asciminib (Scemblix): A third-line treatment option for chronic myeloid leukemia in chronic phase with or without T315I mutation
3个月前
已完结
Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study
3个月前
已完结
Progress of antibody–drug conjugates (ADCs) targeting c-Met in cancer therapy; insights from clinical and preclinical studies
4个月前
已完结
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer
5个月前
已完结
皖公网安备34019202002308
